Page last updated: 2024-08-24

ibandronic acid and Neoplasms

ibandronic acid has been researched along with Neoplasms in 22 studies

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's9 (40.91)18.2507
2000's7 (31.82)29.6817
2010's5 (22.73)24.3611
2020's1 (4.55)2.80

Authors

AuthorsStudies
Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T1
Felsenberg, D; Gabbert, TI; Hoffmeister, B1
Curtis, D; Lu, Y; Qiao, D; Wang, Z; Wen, X; Yao, Y; Zhao, H1
Gerner, C; Grunt, T; Haider, F; Karlic, H; Proestling, K; Thaler, R; Varga, F1
Galiti, D; Galitis, E; Karampeazis, A; Labropoulos, S; Migliorati, C; Nicolatou-Galitis, O; Razis, E; Sgouros, J; Tsimpidakis, A1
Antràs, L; Diel, IJ; Duh, MS; Green, J; Köppler, H; Neary, M; Smith, M; Weide, R; Wintfeld, N1
Grätz, KW; Jacobsen, C; Metzler, P; Obwegeser, J; Rössle, M; Zemann, W1
Berenson, JR1
Bergström, B; Pecherstorfer, M; Rizzoli, R; Steinhauer, EU; Wetterwald, M1
Heidenreich, A; Ohlmann, CH1
Guay, DR1
Kouloulias, V; Kouskouni, E; Mystakidou, K; Parpa, E; Stathopoulou, E; Vlahos, L1
Baumgartner, G; Blind, E; Pecherstorfer, M; Raue, F; Schilling, T; Ziegler, R; Zimmer-Roth, I1
Clemens, MR; Ghielmini, M; Jaeger, P; Krahl, D; Manegold, C; Scharla, SH; Schöter, KH; Thiébaud, D; Wüster, C1
Blind, E; Meinel, T; Raue, F; Wüster, C; Ziegler, R1
Body, JJ; Clemens, MR; Degardin, M; Herrmann, Z; Huss, HJ; Manegold, C; Pecherstorfer, M; Steinhauer, EU; Thiébaud, D; Thürlimann, B; Tubiana-Hulin, M; van Eijkeren, M1
Irzyniec, T; Kokot, F; Wiecek, A; Wnuk, RS1
Burckhardt, P; Fioroni, P; Juillerat, L; Leuenberger, P; Ludwig, H; Markert, M; Pecherstorfer, M; Sauty, A; Thiebaud, D; Zimmer-Roth, I1
Burckhardt, P1
Balfour, JA; Dooley, M1
Body, JJ; Bundred, N; Clemens, MR; Degardin, M; Eghbali, H; Herrmann, Z; Huss, HJ; Manegold, C; Pecherstorfer, M; Rizzoli, R; Rückert, F; Steinhauer, EU; Thiébaud, D; Thürlimann, B; Tubiana-Hulin, M1
Body, JJ1

Reviews

9 review(s) available for ibandronic acid and Neoplasms

ArticleYear
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
    Archives of osteoporosis, 2023, 01-10, Volume: 18, Issue:1

    Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Male; Neoplasms; Network Meta-Analysis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Zoledronic Acid

2023
Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
    The oncologist, 2015, Volume: 20, Issue:4

    Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid

2015
Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review.
    Oral surgery, oral medicine, oral pathology and oral radiology, 2015, Volume: 120, Issue:6

    Topics: Aged; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Fatal Outcome; Female; Humans; Ibandronic Acid; Imidazoles; Male; Middle Aged; Neoplasms; Periodontal Diseases; Radiography, Panoramic; Retrospective Studies; Tooth Extraction; Zoledronic Acid

2015
Treatment of hypercalcemia of malignancy with bisphosphonates.
    Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 21

    Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid

2002
Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.
    Expert review of anticancer therapy, 2004, Volume: 4, Issue:6

    Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Infusions, Intravenous; Neoplasms; Osteoporosis; Product Surveillance, Postmarketing; Risk Factors

2004
Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Pharmacotherapy, 2006, Volume: 26, Issue:5

    Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Interactions; Humans; Hypercalcemia; Ibandronic Acid; Injections, Intravenous; Neoplasms; Osteoporosis

2006
Ibandronate in oncology.
    Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl

    Topics: Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Neoplasms; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic

1997
Ibandronate.
    Drugs, 1999, Volume: 57, Issue:1

    Topics: Animals; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Male; Neoplasms; Osteitis Deformans; Osteoporosis, Postmenopausal

1999
Current and future directions in medical therapy: hypercalcemia.
    Cancer, 2000, Jun-15, Volume: 88, Issue:12 Suppl

    Topics: Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid

2000

Trials

6 trial(s) available for ibandronic acid and Neoplasms

ArticleYear
Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2003, Volume: 11, Issue:8

    Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Male; Middle Aged; Neoplasms; Pamidronate; Treatment Outcome

2003
Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease.
    Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:12

    Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Male; Neoplasms; Prognosis; Prospective Studies; Quality of Life

2008
Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia.
    Bone and mineral, 1993, Volume: 22, Issue:2

    Topics: Aged; Bone Resorption; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Injections, Intravenous; Male; Middle Aged; Neoplasms

1993
Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Bone Resorption; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Hypercalcemia; Ibandronic Acid; Male; Middle Aged; Nausea; Neoplasms; Recurrence; Regression Analysis; Thrombocytopenia; Treatment Outcome

1996
Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.
    Bone, 1996, Volume: 18, Issue:2

    Topics: Aged; Aged, 80 and over; Bone Resorption; Clodronic Acid; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Interleukin-1; Interleukin-6; Male; Middle Aged; Neoplasms; Pamidronate; Tumor Necrosis Factor-alpha

1996
Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
    The Journal of clinical endocrinology and metabolism, 1999, Volume: 84, Issue:10

    Topics: Absorption; Calcium; Cohort Studies; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Kidney Tubules; Male; Middle Aged; Neoplasms; Parathyroid Hormone-Related Protein; Proteins; Recurrence; Syndrome; Treatment Outcome

1999

Other Studies

7 other study(ies) available for ibandronic acid and Neoplasms

ArticleYear
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:4

    Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid

2015
Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells.
    Cancer genetics, 2015, Volume: 208, Issue:5

    Topics: Antineoplastic Agents; Cell Line, Tumor; Diphosphonates; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Epigenesis, Genetic; Fatty Acids; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ibandronic Acid; Lovastatin; Mevalonic Acid; MicroRNAs; NADP; Neoplasms; Protein Processing, Post-Translational; Simvastatin; Vitamin D

2015
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2009, Volume: 17, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Cancer Care Facilities; Creatinine; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Middle Aged; Multivariate Analysis; Neoplasms; Proportional Hazards Models; Renal Insufficiency; Retrospective Studies; Zoledronic Acid

2009
Osteopathology induced by bisphosphonates and dental implants: clinical observations.
    Clinical oral investigations, 2013, Volume: 17, Issue:1

    Topics: Actinomycosis; Administration, Intravenous; Administration, Oral; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Debridement; Dental Implants; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Male; Mandible; Mandibular Neoplasms; Maxilla; Neoplasms; Osteomyelitis; Osteoporosis; Pamidronate; Risk Factors; Time Factors; Zoledronic Acid

2013
Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients.
    The Journal of clinical endocrinology and metabolism, 1994, Volume: 78, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Life Expectancy; Male; Middle Aged; Neoplasms; Pamidronate; Parathyroid Hormone-Related Protein; Proteins; Survival Rate

1994
Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1993, Volume: 25, Issue:1

    Topics: Adult; Aged; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Male; Middle Aged; Neoplasms; Parathyroid Hormone-Related Protein; Proteins

1993
[Use of third generation bisphosphonates in treatment of neoplastic hypercalcemia].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1995, Volume: 50, Issue:44-47

    Topics: Adult; Aged; Calcium; Creatinine; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Male; Middle Aged; Neoplasms

1995